Base de dados : MEDLINE
Pesquisa : D10.532.515 [Categoria DeCS]
Referências encontradas : 25993 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2600 ir para página                         

  1 / 25993 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29203751
[Au] Autor:Placzkowska S; Pawlik-Sobecka L; Kokot I; Piwowar A
[Ad] Endereço:Diagnostyczne Laboratorium Naukowo-Dydaktyczne, Wydzial Farmaceutyczny Z Oddzialem Analityki Medycznej, Uniwersytet Medyczny We Wroclawiu, Wroclaw, Polska.
[Ti] Título:[Metabolic syndrome - a new look at a known problem].
[So] Source:Wiad Lek;70(5):970-976, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:Civilization changes over the past decades have been associated with an increase in the incidence of various metabolic disorders, especially in the carbohydrate-lipid metabolism, which are not always associated with obesity. Metabolic syndrome, despite changing criteria of recognition, is a clinically established risk factor for civilization diseases development. On the other side, the incidence of complex metabolic disorders in non-obese people is increasing, which is referred to in the literature as metabolic obesity with normal body mass. Both, excess visceral fatty tissue and insulin resistance are common components in the diagnosis of these syndromes and their occurrence is associated with an increased risk of developing type 2 diabetes and cardiovascular disease. Some researchers also point out the possibility of occurrence of so-called metabolically healthy obesity. Identify people with such a constellation of disorders is still difficult in clinical practice because of different and changing diagnostic criteria. Data from the literature about epidemiology of these disorders are inconclusive and do not allow for a reliable assessment of such disorders prevalence in population. The increasing rate of the metabolic syndrome and metabolic obesity with normal body weight occurrence in the general population pays attention to the importance of this problem, especially in primary health care. Preventive programs are primarily aimed at older people with high risk of cardiovascular diseases development and focused on detecting metabolic syndrome traits. Nevertheless, very often, young, potentially healthy individuals, are not subject to screening programs, even though incidence of metabolic obesity with normal body weight in this population is very high nowadays.
[Mh] Termos MeSH primário: Peso Corporal
Síndrome Metabólica/metabolismo
Obesidade/metabolismo
[Mh] Termos MeSH secundário: Índice de Massa Corporal
Doenças Cardiovasculares/prevenção & controle
Seres Humanos
Lipoproteínas HDL/metabolismo
Lipoproteínas LDL/metabolismo
Síndrome Metabólica/complicações
Obesidade/complicações
Fatores de Risco
Triglicerídeos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Lipoproteins, HDL); 0 (Lipoproteins, LDL); 0 (Triglycerides)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  2 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329335
[Au] Autor:Kyrklund M; Kummu O; Kankaanpää J; Akhi R; Nissinen A; Turunen SP; Pussinen P; Wang C; Hörkkö S
[Ad] Endereço:Medical Microbiology and Immunology, Research Unit of Biomedicine, Faculty of Medicine, University of Oulu, Oulu, Finland.
[Ti] Título:Immunization with gingipain A hemagglutinin domain of Porphyromonas gingivalis induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein.
[So] Source:PLoS One;13(1):e0191216, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Treatment of periodontitis has beneficial effects on systemic inflammation markers that relate to progression of atherosclerosis. We aimed to investigate whether immunization with A hemagglutinin domain (Rgp44) of Porphyromonas gingivalis (Pg), a major etiologic agent of periodontitis, would lead to an antibody response cross-reacting with oxidized low-density lipoprotein (OxLDL) and how it would affect the progression of atherosclerosis in low-density lipoprotein receptor-deficient (LDLR-/-) mice. The data revealed a prominent IgM but not IgG response to malondialdehyde-acetaldehyde modified LDL (MAA-LDL) after Rgp44 and Pg immunizations, implying that Rgp44/Pg and MAA adducts may share cross-reactive epitopes that prompt IgM antibody production and consequently confer atheroprotection. A significant negative association was observed between atherosclerotic lesion and plasma IgA to Rgp44 in Rgp44 immunized mice, supporting further the anti-atherogenic effect of Rgp44 immunization. Plasma IgA levels to Rgp44 and to Pg in both Rgp44- and Pg-immunized mice were significantly higher than those in saline control, suggesting that IgA to Rgp44 could be a surrogate marker of immunization in Pg-immunized mice. Distinct antibody responses in plasma IgA levels to MAA-LDL, to Pg lipopolysaccharides (Pg-LPS), and to phosphocholine (PCho) were observed after Rgp44 and Pg immunizations, indicating that different immunogenic components between Rpg44 and Pg may behave differently in regard of their roles in the development of atherosclerosis. Immunization with Rgp44 also displayed atheroprotective features in modulation of plaque size through association with plasma levels of IL-1α whereas whole Pg bacteria achieved through regulation of anti-inflammatory cytokine levels of IL-5 and IL-10. The present study may contribute to refining therapeutic approaches aiming to modulate immune responses and inflammatory/anti-inflammatory processes in atherosclerosis.
[Mh] Termos MeSH primário: Adesinas Bacterianas/imunologia
Anticorpos Antibacterianos/biossíntese
Proteínas de Bactérias/imunologia
Cisteína Endopeptidases/imunologia
Imunoglobulina M/biossíntese
Lipoproteínas LDL/imunologia
Porphyromonas gingivalis/imunologia
[Mh] Termos MeSH secundário: Acetaldeído/análogos & derivados
Adesinas Bacterianas/química
Animais
Anticorpos Antibacterianos/metabolismo
Aterosclerose/etiologia
Aterosclerose/imunologia
Aterosclerose/prevenção & controle
Proteínas de Bactérias/química
Infecções por Bacteroidaceae/complicações
Infecções por Bacteroidaceae/imunologia
Infecções por Bacteroidaceae/microbiologia
Reações Cruzadas
Cisteína Endopeptidases/química
Modelos Animais de Doenças
Feminino
Seres Humanos
Imunização
Imunoglobulina M/metabolismo
Lectinas/química
Lectinas/imunologia
Lipoproteínas LDL/química
Malondialdeído/análogos & derivados
Malondialdeído/imunologia
Camundongos
Camundongos Knockout
Periodontite/complicações
Periodontite/imunologia
Periodontite/microbiologia
Domínios Proteicos
Receptores de LDL/deficiência
Receptores de LDL/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adhesins, Bacterial); 0 (Antibodies, Bacterial); 0 (Bacterial Proteins); 0 (Immunoglobulin M); 0 (Lectins); 0 (Lipoproteins, LDL); 0 (Receptors, LDL); 0 (hemagglutinin A, Porphyromonas gingivalis); 0 (malondialdehyde-low density lipoprotein, mouse); 4Y8F71G49Q (Malondialdehyde); EC 3.4.22.- (Cysteine Endopeptidases); EC 3.4.22.37 (argingipain, Porphyromonas gingivalis); GO1N1ZPR3B (Acetaldehyde)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191216


  3 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28469097
[Au] Autor:Yi YH; Yang Z; Han YW; Huai J
[Ad] Endereço:Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.
[Ti] Título:Effects of Rapamycin on Clinical Manifestations and Blood Lipid Parameters in Different Preeclampsia-like Mouse Models.
[So] Source:Chin Med J (Engl);130(9):1033-1041, 2017 May 05.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The pathogenesis of some types of preeclampsia is related to fatty acid oxidation disorders. Rapamycin can regulate fatty acid metabolism. This study aimed to investigate the effects of rapamycin on the clinical manifestations and blood lipid parameters in different preeclampsia-like mouse models. METHODS: Two preeclampsia-like mouse models and a control group were established: L-NA (injected with Nω-nitro-L-arginine methyl ester), LPS (injected with lipopolysaccharide), and the control group with normal saline (NS). The mouse models were established at preimplantation (PI), early- and late-pregnancy (EP, LP) according to the time of pregnancy. The administration of rapamycin (RA; L-NA+RA, LPS+RA, and NS+RA) or vehicle as controls (C; L-NA+C, LPS+C, NS+C) were followed on the 2nd day after the mouse models' establishment. Each subgroup consisted of eight pregnant mice. The mean arterial pressure (MAP), 24-h urinary protein, blood lipid, fetus, and placental weight were measured. The histopathological changes and lipid deposition of the liver and placenta were observed. Student's t-test was used for comparing two groups. Repeated measures analysis of variance was used for blood pressure analysis. Qualitative data were compared by Chi-square test. RESULTS: The MAP and 24-h urinary protein in the PI, EP, and LP subgroups of the L-NA+C and LPS+C groups were significantly higher compared with the respective variables in the NS+C group (P < 0.05). The preeclampsia-like mouse models were established successfully. There was no significant difference in the MAP between the PI, EP, and LP subgroups of the L-NA+RA and L-NA+C groups and the LPS+RA and LPS+C groups. The 24-h urine protein levels in the PI and EP subgroups of the L-NA+RA group were significantly lower compared with the respective levels in the L-NA+C groups (1037 ± 63 vs. 2127 ± 593 µg; 976 ± 42 vs. 1238 ± 72 µg; bothP < 0.05), also this effect appeared similar in the PI and EP subgroups of the LPS+RA and LPS+C groups (1022 ± 246 vs. 2141 ± 432 µg; 951 ± 41 vs. 1308 ± 30 µg; bothP < 0.05). The levels of serum-free fatty acid (FFA) in the PI and EP subgroups of the L-NA+RA groups were significantly lower compared with the respective levels in the L-NA+C group (2.49 ± 0.44 vs. 3.30 ± 0.18 mEq/L; 2.23 ± 0.29 vs. 2.84 ± 0.14 mEq/L; bothP < 0.05). The levels of triglycerides (TG) and total cholesterol in the PI subgroup of the L-NA+RA group were significantly lower compared with the respective levels in the L-NA+C (1.51 ± 0.16 vs. 2.41 ± 0.37 mmol/L; 2.11 ± 0.17 vs. 2.47 ± 0.26 mmol/L; bothP < 0.05), whereas high-density lipoprotein serum concentration was significantly higher (1.22 ± 0.19 vs. 0.87 ± 0.15 mmol/L;P < 0.05) and low-density lipoprotein serum concentration did not exhibit a significant difference. There were no significant differences in the FFA of the PI, EP, and LP subgroups between the LPS+RA and the LPS+C groups. The levels of TG in the PI subgroup of the LPS+RA group were significantly lower compared with the respective levels in the LPS+C group (0.97 ± 0.05 vs. 1.22 ± 0.08 mmol/L;P < 0.05). CONCLUSION: Rapamycin can improve clinical manifestations and blood lipid profile in part of the preeclampsia-like mouse models.
[Mh] Termos MeSH primário: Lipídeos/sangue
Pré-Eclâmpsia/sangue
Pré-Eclâmpsia/tratamento farmacológico
Sirolimo/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Pressão Sanguínea/efeitos dos fármacos
Distribuição de Qui-Quadrado
Colesterol/sangue
Modelos Animais de Doenças
Feminino
Metabolismo dos Lipídeos/efeitos dos fármacos
Lipoproteínas HDL/sangue
Lipoproteínas LDL/sangue
Camundongos
Camundongos Endogâmicos C57BL
Placenta/efeitos dos fármacos
Placenta/metabolismo
Gravidez
Resultado da Gravidez
Triglicerídeos/administração & dosagem
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lipids); 0 (Lipoproteins, HDL); 0 (Lipoproteins, LDL); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.4103/0366-6999.204924


  4 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258822
[Au] Autor:Huangfu N; Xu Z; Zheng W; Wang Y; Cheng J; Chen X
[Ad] Endereço:Department of Cardiology, Ningbo First Hospital, Ningbo, PR China.
[Ti] Título:LncRNA MALAT1 regulates oxLDL-induced CD36 expression via activating ß-catenin.
[So] Source:Biochem Biophys Res Commun;495(3):2111-2117, 2018 01 15.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The expression of scavenger receptors in macrophages regulating lipid uptake plays an important role in foam cell formation and the subsequent atherosclerotic plaque formation. Long non-coding RNA MALAT1 is abundantly expressed in THP-1-derived macrophages, and oxidized low-density lipoprotein promotes its transcription by qRT-PCR and RNA FISH detection. Through chemical inhibitor treatments and by performing a dual luciferase reporter analysis, we found that oxLDL induces MALAT1 transcription through the NF-κB pathway. The knockdown of MALAT1 using siRNA transfection affects lipid uptake in macrophages. To understand the details, we checked the scavenger receptors, which mainly control lipid uptake, and found that MALAT1 knockdown decreased CD36 expression. Additionally, we also incubated macrophages with actinomycin D, combined with a dual luciferase reporter analysis, and we found that MALAT1 influenced CD36 expression at the transcription level. We aim to investigate the detailed mechanism by which MALAT1 promotes CD36 transcription, and thus, we designed and synthesized biotin-TEG labeled oligonucleotides to precipitate the MALAT1 RNA-DNA-protein complex in vivo. Combined with SDS-PAGE electrophoresis and a subsequent mass spectra analysis, ß-catenin, a transcription factor that promotes CD36 transcription, was found in the complex. By performing R-IPs, we validated that ß-catenin was bound to MALAT1 under the oxLDL treatment. In addition, using VAX939, a chemical inhibitor of ß-catenin, MALAT1 was demonstrated to promote CD36 transcription partly via ß-catenin. We also performed chips to detect whether MALAT1 affects ß-catenin accumulation in the binding sites of the CD36 promoter and found that MALAT1 knockdown decreases ß-catenin binding to the CD36 promoter and vice versa. In conclusion, oxLDL induced MALAT1 transcription and MALAT1 recruits ß-catenin to binding sites on the CD36 promoter to induce CD36 expression, which enhances lipid uptake in macrophages.
[Mh] Termos MeSH primário: Antígenos CD36/metabolismo
Metabolismo dos Lipídeos/fisiologia
Lipoproteínas LDL/metabolismo
Macrófagos/metabolismo
RNA Longo não Codificante/metabolismo
beta Catenina/metabolismo
[Mh] Termos MeSH secundário: Regulação da Expressão Gênica/fisiologia
Seres Humanos
Células THP-1
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (CD36 Antigens); 0 (CTNNB1 protein, human); 0 (Lipoproteins, LDL); 0 (MALAT1 long non-coding RNA, human); 0 (RNA, Long Noncoding); 0 (beta Catenin); 0 (oxidized low density lipoprotein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE


  5 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29282980
[Au] Autor:Wu GC; Lin SY; Liang HJ; Hou WC
[Ti] Título:135-Day Interventions of Yam Dioscorin and the Dipeptide Asn-Trp (NW) To Reduce Weight Gains and Improve Impaired Glucose Tolerances in High-Fat Diet-Induced C57BL/6 Mice.
[So] Source:J Agric Food Chem;66(3):645-652, 2018 Jan 24.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The C57BL/6J mice were fed a 135-day normal diet or a high-fat diet (HFD) without, or concurrent with, a single yam dioscorin (80 mg/kg) or dipeptide NW (40 mg/kg) intervention every day. The final body weights (g) of mice were 26.1 ± 1.4, 34.97 ± 2.1, 31.75 ± 2.6, and 31.66 ± 3.1, respectively, for normal diet-fed, HFD-fed, dioscorin-intervened, and NW-intervened group. The mice in both intervened groups showed similar less weight gains and had significant differences (P < 0.05) compared to those in the HFD group under the same cumulative HFD intakes. The blood biochemical index of mice with dioscorin interventions showed significantly lower contents in total cholesterol and low-density lipoprotein, and NW interventions showed significantly lower total triglyceride contents compared to those of the HFD group (P < 0.05). Both intervened mice exhibited similar reductions in total visceral lipid contents and have significant differences compared to those of the HFD group (P < 0.05). The dioscorin intervention was better than NW interventions in lowering blood glucose levels by oral glucose tolerance tests and both showed significant differences (P < 0.05) compared to those in the HFD group. Yam dioscorin or dipeptide NW will potentially be used for preventive functional foods of less body weight gains and impaired glucose tolerance controls, which require further clinical trial investigations.
[Mh] Termos MeSH primário: Dioscorea/química
Dipeptídeos/administração & dosagem
Obesidade/tratamento farmacológico
Proteínas de Plantas/química
[Mh] Termos MeSH secundário: Animais
Glicemia/metabolismo
Dieta Hiperlipídica/efeitos adversos
Dipeptídeos/química
Intolerância à Glucose
Seres Humanos
Lipoproteínas LDL/sangue
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Obesidade/metabolismo
Obesidade/fisiopatologia
Proteínas de Plantas/administração & dosagem
Triglicerídeos/sangue
Ganho de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dipeptides); 0 (Lipoproteins, LDL); 0 (Plant Proteins); 0 (Triglycerides); 0 (dioscorin protein, Dioscorea)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b05564


  6 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29363927
[Au] Autor:Chernyak OO; Sentsova TB; Vorozhko IV; Tutelyan VA; Gapparova KM; Borodina SV
[Ti] Título:[Genomic, proteomic and metabolomic predictors of atherosclerosis in obese patients. Part II].
[So] Source:Vopr Pitan;84(5):39-45, 2015.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Currently there is no extensive research of metabolic disorders in obese patients with atherosclerosis, including the study of genomic, biochemical, immune and other markers. Therefore, the aim of the study was to identify the genomic, proteomic and metabolic predictors of atherosclerosis in obese patients. We evaluated condition of the cardiovascular system of the 100 obese patients aged 18 to 66 years, which were divided in two groups of patients: Group 1 consisted of 50 obese patients without vascular pathology, 2nd group consisted of 50 patients with obesity, complicated by atherosclerosis. We carried out a study of the lipid metabolism and analysis of polymorphic alleles ε2, ε3, ε4 of the ApoE gene by PCR. Our data showed that clinically significant predictors of atherosclerosis in obese patients are homozygous genotypes ε2/ε2 of the ApoE gene, increased blood serum level of triglycerides, oxidated LDL, interleukin-6, adhesion molecules SICAM, L-FABP and adiponectin reduction.
[Mh] Termos MeSH primário: Aterosclerose
Metabolômica
Obesidade
Proteômica
[Mh] Termos MeSH secundário: Adiponectina/sangue
Adolescente
Adulto
Idoso
Apolipoproteínas E/sangue
Apolipoproteínas E/genética
Aterosclerose/sangue
Aterosclerose/etiologia
Aterosclerose/genética
Biomarcadores/sangue
Proteínas de Ligação a Ácido Graxo/sangue
Feminino
Seres Humanos
Interleucina-6/sangue
Lipoproteínas LDL/sangue
Masculino
Meia-Idade
Obesidade/sangue
Obesidade/complicações
Obesidade/genética
Polimorfismo Genético
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ADIPOQ protein, human); 0 (Adiponectin); 0 (Apolipoproteins E); 0 (Biomarkers); 0 (Fatty Acid-Binding Proteins); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Lipoproteins, LDL); 0 (Triglycerides); 0 (oxidized low density lipoprotein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE


  7 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220173
[Au] Autor:Primacella M; Wang T; Acevedo NC
[Ad] Endereço:Department of Food Science and Human Nutrition, Iowa State University , 2312 Food Sciences Building, 536 Farm House Lane, Ames, Iowa 5011, United States.
[Ti] Título:Use of Reconstitued Yolk Systems To Study the Gelation Mechanism of Frozen-Thawed Hen Egg Yolk.
[So] Source:J Agric Food Chem;66(2):512-520, 2018 Jan 17.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Yolk gelation upon 5 week freezing-thawing was studied in four recombined yolk systems containing different plasma and granule proportions. Fractionation for mass distribution, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for protein distribution, and rheological properties were explored. Results indicate that both plasma and granule components, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and α-livetin proteins, contributed to gelation. Protein aggregation was reflected through a large mass increase in the granule fraction and appearance of a floating LDL layer upon fractionation of gelated yolk systems. A significant increase in gel strength (elastic modulus, G') was observed with the increase of the granule content. Overall, this study provides a better understanding of yolk gelation mechanism that may consequently lead to the design of innovative methods for preventing gelation. A schematic presentation of the yolk gelation mechanism is also proposed.
[Mh] Termos MeSH primário: Gema de Ovo/química
[Mh] Termos MeSH secundário: Animais
Galinhas
Proteínas do Ovo/química
Eletroforese em Gel de Poliacrilamida
Feminino
Géis/química
Lipoproteínas HDL/química
Lipoproteínas LDL/química
Peso Molecular
Reologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Egg Proteins); 0 (Gels); 0 (Lipoproteins, HDL); 0 (Lipoproteins, LDL); 9008-28-0 (livetin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b04370


  8 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29174964
[Au] Autor:Miao H; Zeng H; Gong H
[Ad] Endereço:Department of Cardiology, Jinshan Hospital, Fudan University, Shanghai, China.
[Ti] Título:microRNA-212 promotes lipid accumulation and attenuates cholesterol efflux in THP-1 human macrophages by targeting SIRT1.
[So] Source:Gene;643:55-60, 2018 Feb 15.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Macrophage foam cell formation is a key initiating event in the pathogenesis of atherosclerosis. This work was conducted to determine the role of microRNA (miR)-212 in the transformation of foam cells from macrophages. We examined the expression of miR-212 in atherosclerotic lesions in an apoE-deficient (apoE ) mouse model. The effects of miR-212 overexpression and knockdown on lipid accumulation and cholesterol homeostasis in THP-1 macrophages after exposure to oxidized low-density lipoprotein (oxLDL). The mechanism underlying the activity of miR-212 was explored. It was found that miR-212 was downregulated in atherosclerotic lesions and macrophages from apoE mice fed high-fat diet, compared to the equivalents from apoE mice fed standard diet. Overexpression of miR-212 promoted lipid accumulation in oxLDL-treated THP-1 macrophages, whereas miR-212 depletion exerted an opposite effect. Macrophage cholesterol efflux to apolipoprotein A-I was significantly reduced by miR-212, which was accompanied by reduced ABCA1 expression. Mechanistically, miR-212 targeted sirtuin 1 (SIRT1) to repress the expression of ABCA1 in THP-1 macrophages. Rescue experiments confirmed that co-expression of SIRT1 attenuated lipid accumulation and restored cholesterol efflux in miR-212-overexpressing THP-1 macrophages. Collectively, miR-212 facilitates macrophage foam cell formation and suppresses ABCA1-dependent cholesterol efflux through downregulation of SIRT1. Targeting miR-212 may provide a potential therapeutic strategy for atherosclerosis.
[Mh] Termos MeSH primário: Colesterol/metabolismo
Metabolismo dos Lipídeos/genética
MicroRNAs/metabolismo
Sirtuína 1/metabolismo
Células THP-1/metabolismo
[Mh] Termos MeSH secundário: Transportador 1 de Cassete de Ligação de ATP/genética
Transportador 1 de Cassete de Ligação de ATP/metabolismo
Animais
Apolipoproteína A-I/genética
Apolipoproteína A-I/metabolismo
Aterosclerose/genética
Colesterol/genética
Dieta Hiperlipídica
Células Espumosas/metabolismo
Seres Humanos
Hipercolesterolemia/metabolismo
Hipercolesterolemia/patologia
Lipoproteínas LDL/farmacologia
Masculino
Camundongos
Camundongos Knockout
MicroRNAs/genética
Sirtuína 1/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCA1 protein, human); 0 (APOA1 protein, human); 0 (ATP Binding Cassette Transporter 1); 0 (Apolipoprotein A-I); 0 (Lipoproteins, LDL); 0 (MIRN212 microRNA, human); 0 (MicroRNAs); 0 (oxidized low density lipoprotein); 97C5T2UQ7J (Cholesterol); EC 3.5.1.- (SIRT1 protein, human); EC 3.5.1.- (Sirtuin 1)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  9 / 25993 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29247892
[Au] Autor:Wang WQ; Yin YP; Jun L; Xuan LJ
[Ad] Endereço:State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Shanghai 201203, PR China.
[Ti] Título:Halimane-type diterpenoids from Vitex rotundifolia and their anti-hyperlipidemia activities.
[So] Source:Phytochemistry;146:56-62, 2018 Feb.
[Is] ISSN:1873-3700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vitex rotundifolia is the variant of the traditional Chinese medicine (TCM) Vitex trifolia. Diterpenoids from V. trifolia have shown anti-hyperlipidemia activity. As part of a continuous research program of searching for anti-hyperlipidemia constituents from TCM, 95% alcohol extract of the fruits of V. rotundifolia was fully studied, and 18 diterpenoids were isolated, including eight previously undescribed compounds (viterofolins A-H). Among them, viterofolins A-B were previously undescribed rearranged halimane-type diterpenoids, viterofolins CH were previously undescribed halimane-type diterpenoids. These compounds were then firstly evaluated in lipid (Dil-LDL) uptake assay in HepG2 cells. Viterofolin H, (5S, 6R, 8R, 9R, 10S)-6-acetoxy-9-hydroxy-13 (14)-labden-16,15-olide and previtexilactone showed moderate activities in promoting LDL uptake (1.27-1.35 fold). This work laid the foundation for searching anti-hyperlipidemia natural products.
[Mh] Termos MeSH primário: Produtos Biológicos/farmacologia
Diterpenos/farmacologia
Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/farmacologia
Lipoproteínas LDL/metabolismo
Vitex/química
[Mh] Termos MeSH secundário: Produtos Biológicos/química
Produtos Biológicos/isolamento & purificação
Diterpenos/química
Diterpenos/isolamento & purificação
Células Hep G2
Seres Humanos
Hiperlipidemias/metabolismo
Hipolipemiantes/química
Hipolipemiantes/isolamento & purificação
Medicina Tradicional Chinesa
Estrutura Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Diterpenes); 0 (Hypolipidemic Agents); 0 (Lipoproteins, LDL); 0 (halimane)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE


  10 / 25993 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235790
[Au] Autor:Grytsay VI
[Ti] Título:A mathematical model of the metabolic process of atherosclerosis.
[So] Source:Ukr Biochem J;88(4):75-84, 2016 Jul-Aug.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:A mathematical model of the metabolic process of atherosclerosis is constructed. The functioning of the polyenzymatic prostacyclin-thromboxane system of blood and the influence of a level of "bad cholesterol", namely low density lipoproteins (LDL), on it are studied. With the help of the numerical experiment, we analyze the influence of the concentration of molecules of fat on hemostasis of blood in blood vessels. The kinetic curves for components of the system, phase-periodic bifurcation diagrams, attractors for various modes, and Poincaré cross-section and image of a strange attractor are constructed. The complete spectra of Lyapunov's exponents, divergencies, KS-entropies, predictability horizons, and Lyapunov dimensions of the fractality of strange attractors are calculated. Conclusions about the structural-functional connections, which determine the dependence of hemostasis of a circulatory system on the level of cholesterol in blood are drawn.
[Mh] Termos MeSH primário: Aterosclerose/diagnóstico
Lipoproteínas LDL/sangue
Modelos Estatísticos
Prostaglandinas I/sangue
Tromboxanos/sangue
[Mh] Termos MeSH secundário: Aterosclerose/sangue
Aterosclerose/patologia
Vasos Sanguíneos/metabolismo
Vasos Sanguíneos/patologia
Simulação por Computador
Hemostasia/fisiologia
Homeostase/fisiologia
Seres Humanos
Cinética
Dinâmica não Linear
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lipoproteins, LDL); 0 (Prostaglandins I); 0 (Thromboxanes)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.04.075



página 1 de 2600 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde